@FierceBiotech: ICYMI: Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. Story | Follow @FierceBiotech
@JohnCFierce: Alzheimer's startup Alzheon bags $10M and beats a path to Phase III. Article | Follow @JohnCFierce
@DamianFierce: ICYMI: Life sciences entrepreneurs, here is my gift to you: The Biotech Name Generator | Follow @DamianFierce
> Halozyme ($HALO) is back on track for a Phase III trial on its lead pancreatic cancer treatment, detailing its plans to the FDA after the agency lifted a hold on the drug's development. More
> Roche ($RHHBY) wrapped up its deal to take a $1.2 billion stake in Foundation Medicine ($FMI), planning to hand over $150 million over 5 years in a broad R&D collaboration. News
> FierceMedicalDevices takes a look at the world's top med tech companies by 2014 revenue. Report
Medical Device News
@FierceMedDev: FDA approves breath test for stomach disorder, highlights its ease of use over standard of care. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: Alere earns FDA clearance for rapid diagnostic of Strep A. FierceDiagnostics story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs. Article | Follow @EmilyWFierce
> FDA recalls fall more than 50% in Q1 2015 after reaching record high in 2014. More
> Study: False alarms of breast cancer costing U.S. $4B a year. Story
> Medtronic debuts European study of its atrial fibrillation device. Article
Pharma News
@FiercePharma: ICYMI from FiercePharmaManufacturing: UAE drug distributor building a $20M plant in Dubai. Report | Follow @FiercePharma
@EricPFierce: Hospira has now received FDA warning letters for plants on 4 of 7 continents. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Shire could use boost from adult ADHD med to hit $10B goal. Report | Follow @CarlyHFierce
> Watch out for a two-front hep C price war when Merck's combo hits. Article
> Novo's Tresiba news injects uncertainty in insulin market, particularly for Sanofi. Story
Pharma Marketing News
> Next DTC push for Linzess: Spotlight patients, with big salesforce backup. More
> Pfizer, Merck KGaA suit up for Xalkori marketing wave. Report
> Does pricier mean better to ad consumers? FDA means to find out. Article
> Patient portals open door to lasting relationships with patients, 'Digital Doctor' says. Story
> Pfizer wants Canadians to think EpiPen. What else but a hockey partnership? More
Biotech Research News
> Zurich investigators ID pathway for B cell lymphoma. Item
> Berkeley, Harvard groups highlight new targets for cachexia. Report
> Regulus surges after AstraZeneca snags rights to NASH drug. More
> Whitehead team adapts CRISPR-Cas9 tech to target killer fungal infections. Article
> Daiichi Sankyo partners with Sanford-Burnham on a cardio molecule. Story
Diagnostics News
> Researchers develop paper microchip and smartphone diagnostic for HIV. Item
> OpGen eyes $35M IPO for drug-resistant bacteria tests. Story
> Roche and Foundation Medicine seal $1.2B deal with plans for cancer R&D. More
> Alere earns FDA clearance for rapid diagnostic of Strep A. News
> Natera ropes in $55M with eye on cancer Dx. Article